136 related articles for article (PubMed ID: 4074637)
1. Development of drug resistance in a murine mammary tumour.
McMillan TJ; Stephens TC; Steel GG
Br J Cancer; 1985 Dec; 52(6):823-32. PubMed ID: 4074637
[TBL] [Abstract][Full Text] [Related]
2. Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
Stephens TC; Adams K; Peacock JH
Br J Cancer; 1986 Feb; 53(2):237-45. PubMed ID: 3954945
[TBL] [Abstract][Full Text] [Related]
3. Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.
McMillan TJ; Stephens TC; Steel GG
Br J Cancer; 1986 Jun; 53(6):753-9. PubMed ID: 3718828
[TBL] [Abstract][Full Text] [Related]
4. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
5. The gross and cellular response of a rat mammary tumour to single doses of cyclophosphamide.
Moore JV; Dixon B
Eur J Cancer (1965); 1978 Jan; 14(1):91-5. PubMed ID: 624306
[No Abstract] [Full Text] [Related]
6. Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour.
Miller BE; Miller FR; Machemer T; Heppner GH
Br J Cancer; 1993 Jul; 68(1):18-25. PubMed ID: 8318410
[TBL] [Abstract][Full Text] [Related]
7. Host immune potentiation of drug responses to a murine mammary adenocarcinoma.
Radov LA; Haskill JS; Korn JH
Int J Cancer; 1976 Jun; 17(6):773-9. PubMed ID: 947856
[No Abstract] [Full Text] [Related]
8. Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival.
Twentyman PR
Br J Cancer; 1980 Aug; 42(2):297-304. PubMed ID: 7426337
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
Tobias JS; Parker LM; Tattersall MH; Frei E
Br J Cancer; 1975 Aug; 32(2):199-207. PubMed ID: 1212350
[TBL] [Abstract][Full Text] [Related]
10. [Induced resistance of experimental tumors to nitrosomethylurea].
Krutova TV; Ostrovskaia LA
Vopr Onkol; 1982; 28(11):48-52. PubMed ID: 7147832
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
12. Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.
Luk CK; Tannock IF
Br J Cancer; 1988 Aug; 58(2):133-8. PubMed ID: 3166902
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of a solid murine tumor with cyclophosphamide and radiation: the effects of time, dose and assay method.
Begg AC; Fu KK; Shrieve DC; Phillips TL
Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1433-9. PubMed ID: 536253
[No Abstract] [Full Text] [Related]
14. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
Castellino SM; Friedman HS; Elion GB; Ong ET; Marcelli SL; Page R; Bigner DD; Dewhirst MW
Br J Cancer; 1995 Jun; 71(6):1181-7. PubMed ID: 7779708
[TBL] [Abstract][Full Text] [Related]
15. The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
McNally NJ
Br J Cancer; 1982 Oct; 46(4):670-4. PubMed ID: 6291565
[No Abstract] [Full Text] [Related]
16. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
17. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.
Graham CH; Kobayashi H; Stankiewicz KS; Man S; Kapitain SJ; Kerbel RS
J Natl Cancer Inst; 1994 Jul; 86(13):975-82. PubMed ID: 8007019
[TBL] [Abstract][Full Text] [Related]
18. CB 1954 revisited. II. Toxicity and antitumour activity.
Workman P; Morgan JE; Talbot K; Wright KA; Donaldson J; Twentyman PR
Cancer Chemother Pharmacol; 1986; 16(1):9-14. PubMed ID: 3940225
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
Friery OP; Gallagher R; Murray MM; Hughes CM; Galligan ES; McIntyre IA; Patterson LH; Hirst DG; McKeown SR
Br J Cancer; 2000 Apr; 82(8):1469-73. PubMed ID: 10780528
[TBL] [Abstract][Full Text] [Related]
20. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
